product
DiscoverX GPCRscan® GPCR Profiling Services
22 February 2016 | By DiscoverX Corporation
GPCRscan is a functional cell-based GPCR assay panel for profiling drug compounds during drug discovery...
List view / Grid view
Screening
product
DiscoverX BioMAP® Diversity PLUS Panel
19 February 2016 | By DiscoverX Corporation
Diversity PLUS Panel contains 12 human primary cell systems from multiple tissues that model human disease for predictive insight into drug efficacy and MOA...
product
DiscoverX PathHunter® Checkpoint Signaling Assays
19 February 2016 | By DiscoverX Corporation
PathHunter® Checkpoint Assays enable screening and potency assays for the development of immunotherapy drugs...
whitepaper
Handbook: An introduction to Antibodies and their applications, 3rd ed
A concise overview of some of the key features for the use of antibodies and immunochemical techniques in biological research...
news
Drug discovery crisis linked to bad technology choices
15 February 2016 | By Victoria White
Researchers say drug discovery processes are becoming unsustainably expensive despite huge technological advances because the wrong methods are being used…
article
The relevance of homogeneous radiometric assays in modern drug discovery
In the past two decades, several alternative, non-radiometric assay formats have been developed for the high-throughput screening (HTS) of target classes such as protein kinases, which were previously screened using radiometric assays. Radiometric screening (and the expertise to perform such HTS) has thus declined in recent years...
article
Finding a cure for neglected tropical diseases with cell-based assays
Neglected tropical diseases pose a significant threat to public health and affect nearly one billion people in tropical and sub-tropical regions throughout the world. There is a pressing need to identify new therapeutics for NTDs and many developed nations are participating in drug discovery efforts...
product
DiscoverX BioMAP® Phenotypic Profiling Services
12 February 2016 | By DiscoverX Corporation
If you are looking to advance compounds to the clinic, BioMAP® phenotypic profiling services will predict the behaviour of your drug candidates in patients...
product
DiscoverX PathHunter® Bioassays for Biologics
12 February 2016 | By DiscoverX Corporation
PathHunter® bioassays are cell-based assays that are highly validated, simple, and target specific to support biologics drug development...
article
canSAR: a portal to Big Data for drug discovery
9 February 2016 | By Dr Bissan Al-Lazikani and Elizabeth Coker, The Institute of Cancer Research, London
Dr Bissan Al-Lazikani and Elizabeth Coker discuss canSAR: the first public domain example of Big Data for drug discovery...
article
Antibody fragment technology and avian IgY antibodies: a powerful combination
Recombinant monoclonal antibodies or antibody biologics have been successfully developed as diagnostic and therapeutic agents...
news
Stem cells that can repair the skull and face bones
1 February 2016 | By Victoria White
Scientists have, for the first time, identified and isolated stem cells capable of skull formation and craniofacial bone repair in mice...
news
Pfizer to give a keynote address on reviving covalent drug design in oncology at SMi’s 15th annual event this February
29 January 2016 | By SMi Group
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference...
news
Karolinska Institutet and Biovica to evaluate promising cancer treatments
29 January 2016 | By Victoria White
The lab headed by Thomas Helleday at Karolinska Institutet and Biovica are to collaborate to improve evaluation of new, promising cancer therapies...
news
ADDoPT project set to transform the UK pharma industry
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
